Clinical Trials
9 trialsNCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT02973789 2026-03-18
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Phase 3 Completed
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT04225039 2025-08-15
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
Phase 2 Active not recruiting
NCT04020185 2024-12-11
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
Phase 1/2 Completed
NCT04193293 2023-09-21
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
SecuraBio
Phase 1/2 Terminated
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated